NZE · BLT.NZ · NZD
Stock price, earnings
Quote as of Oct 30, 2026, 02:58 AM UTC. Cached market data; not a live quote.
One-year closing-price history · NZD. Historical prices are not a forecast.
BLIS Technologies Limited’s quoted price sits in the upper half of its reported 52-week range, 25.81% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow BLIS Technologies Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
BLIS Technologies Limited, together with its subsidiaries, specializes in creating and distributing health-focused products. These offerings are underpinned by unique bacterial strains that exhibit bacteriocin activity. The company prominently features several key probiotic strains: BLIS K12, a supplement engineered to bolster ear, nose, and throat well-being in young children, in addition to enhancing immune function and combating halitosis; BLIS M18, an oral probiotic designed to promote robust dental and gum health; and BLIS Q24, a probiotic formulation aimed at harmonizing and rejuvenating the skin's microbiome, thereby fostering healthier, clearer, and more radiant skin. Established in 2000, BLIS Technologies is based in Dunedin, New Zealand, and maintains a global presence with operations spanning New Zealand, the Asia Pacific region, Europe, the Middle East, Africa, and North America.
Latest available per-share figures in NZD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:21 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NZ$47.66+NZ$0.28 (+0.59%)
Fisher & Paykel Healthcare Corporation Limited’s quoted price sits in the upper half of its reported 52-week range, 3.97% below the high.
NZ$1.77+NZ$0.03 (+1.72%)
Ryman Healthcare Limited’s quoted price sits in the lower half of its reported 52-week range, 41.97% below the high.
NZ$6.56+NZ$0.06 (+0.92%)
Summerset Group Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 48.75% below the high.
NZ$4.65-NZ$0.05 (-1.06%)
AFT Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 4.12% below the high.
NZ$0.64-NZ$0.01 (-1.54%)
Oceania Healthcare Limited’s quoted price sits in the lower half of its reported 52-week range, 31.18% below the high.
NZ$0.24NZ$0.00 (0.0%)
Pacific Edge Limited’s quoted price sits in the lower half of its reported 52-week range, 30.88% below the high.
NZ$1.93-NZ$0.01 (-0.26%)
Green Cross Health Limited’s quoted price sits in the upper half of its reported 52-week range, 14.22% below the high.
A$0.55+A$0.02 (+2.8%)
Aroa Biosurgery Limited’s quoted price sits in the lower half of its reported 52-week range, 31.25% below the high.
